Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population by Rochester, MA et al.
BioMed CentralBMC Urology
ssOpen AcceResearch article
Development and validation of risk score for predicting positive 
repeat prostate biopsy in patients with a previous negative biopsy in 
a UK population
Mark A Rochester*1, Nora Pashayan3, Fiona Matthews4, Andrew Doble1 and 
John McLoughlin1,2
Address: 1Department of Urology, Addenbrooke's Hospital, Cambridge, UK, 2Department of Urology, West Suffolk Hospital, Bury St Edmunds, 
UK, 3Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, UK and 4Medical Research Council Biostatistics 
Unit, Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, UK
Email: Mark A Rochester* - rochester@doctors.org.uk; Nora Pashayan - np278@cam.ac.uk; Fiona Matthews - Fiona.Matthews@mrc-
bsu.cam.ac.uk; Andrew Doble - andrew.doble@addenbrookes.nhs.uk; John McLoughlin - john.mcloughlin@addenbrookes.nhs.uk
* Corresponding author    
Abstract
Background: Little evidence is available to determine which patients should undergo repeat
biopsy after initial benign extended core biopsy (ECB). Attempts have been made to reduce the
frequency of negative repeat biopsies using PSA kinetics, density, free-to-total ratios and Kattan's
nomogram, to identify men more likely to harbour cancer but no single tool accurately predicts
biopsy outcome. The objective of this study was to develop a predictive nomogram to identify men
more likely to have a cancer diagnosed on repeat prostate biopsy.
Methods: Patients with previous benign ECB undergoing repeat biopsy were identified from a
database. Association between age, volume, stage, previous histology, PSA kinetics and positive
repeat biopsy was analysed. Variables were entered stepwise into logistic regression models. A risk
score giving the probability of positive repeat biopsy was estimated. The performance of this score
was assessed using receiver characteristic (ROC) analysis.
Results: 110 repeat biopsies were performed in this period. Cancer was detected in 31% of repeat
biopsies at Hospital (1) and 30% at Hospital (2). The most accurate predictive model combined age,
PSA, PSA velocity, free-to-total PSA ratio, prostate volume and digital rectal examination (DRE)
findings. The risk model performed well in an independent sample, area under the curve (AUCROC)
was 0.818 (95% CI 0.707 to 0.929) for the risk model and 0.696 (95% CI 0.472 to 0.921) for the
validation model. It was calculated that using a threshold risk score of > 0.2 to identify high risk
individuals would reduce repeat biopsies by 39% while identifying 90% of the men with prostate
cancer.
Conclusion: An accurate multi-variable predictive tool to determine the risk of positive repeat
prostate biopsy is presented. This can be used by urologists in an outpatient setting to aid decision-
making for men with prior benign histology for whom a repeat biopsy is being considered.
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The majority of the 35000 new diagnoses of prostate can-
cer annually in the UK [1] are made as a result of transrec-
tal ultrasound-guided (TRUS) biopsies of the prostate
performed to investigate an elevated serum PSA or abnor-
mal digital rectal examination. Seventy-five percent of
cancers identified are detected at the first biopsy [2]. The
majority of men undergoing this procedure, however, will
not have a cancer detected and doubt will remain both in
their minds and in those of the clinician as to whether a
further biopsy is required in the setting of a persistently
abnormal or rising serum PSA. Prostate biopsy is not with-
out morbidity [3] carrying a 1% risk of sepsis or severe
haemorrhage, and 5% risk of urinary tract infection, and
the need to reduce unnecessary repeat biopsies was further
highlighted recently in the UK with the publication of
NICE guidelines for prostate cancer [4]. This document
estimated that 89000 prostate biopsies are performed
annually in the UK. Twenty percent of cancers are detected
at the second biopsy session [5], and a number of param-
eters have been promoted to reduce the frequency of
benign repeat biopsy. Abnormal digital rectal examina-
tion (DRE) [6], PSA [5], PSA velocity > 0.75 ng/ml/yr [7],
PSA density > 0.15 [5,7] transition zone density > 0.25
[5,8], and free-to-total PSA ratio [5,7], as well as initial
histological findings of high grade prostatic intraepithe-
lial neoplasia (HGPIN) [6,8] or suspicious histology [9]
have all been used to identify those men at higher risk of
positive repeat biopsy. These individual parameters when
taken alone, have poor positive and negative predictive
value [5]. Kattan has produced a number of predictive
nomograms to aid decision making in prostate cancer
[10], including one intended to enhance prediction of
positive repeat biopsies, based on sextant prostate biopsy
data [11]. It was suggested that the model could be
improved through adding free-to-total PSA ratio and pros-
tate volume to the calculation. The aim of this study was
to use a similar approach for a United Kingdom popula-
tion in order to produce a more accurate predictive tool to
be used in the outpatient setting when faced with a patient
who may be a candidate for a second TRUS and biopsy of
the prostate.
Methods
All patients who underwent first repeat prostate biopsy
sessions at two hospitals in the former West Anglia Cancer
Network with a combined catchment population of more
that 1.25 million were studied. Those who had an initial
negative biopsy were analysed. Indications for repeat
biopsy and the number of biopsy cores taken were similar
in both hospitals according to local guidelines, with an
extended core biopsy template (at least 10 cores including
anterior horn of the peripheral zone). Prostate biopsies
were performed using TRUS guidance with a 7.5 MHz
probe (B&K), biopsy gun (Bard) and an 18 gauge biopsy
needle with local anesthesia.
The clinical parameters recorded for each patient were age,
serum PSA, PSA velocity in ng/ml/year (measured over 18
months), prostate volume, DRE findings, time interval
between biopsy sessions, and history of HGPIN or suspi-
cious histology. Data was collected from an anonymised
database. Research was carried out in compliance with the
Helsinki Declaration.
Developing the risk score
This was based on data obtained from patients undergo-
ing repeat biopsy at Hospital (1) in the former West
Anglia Cancer Network during 2007. Using univariate
analysis, the association between the study variables (age,
prostate volume, DRE findings (clinically benign referred
to as stage 1, and a palpable abnormality stage 2), previ-
ous suspicious biopsy, previous high grade PIN, PSA, free-
to-total PSA, PSA density, PSA velocity) and the outcome
of repeat biopsy was studied. These variables were subse-
quently entered stepwise into logistic regression models.
For each model, the mean probability of having a positive
repeat biopsy was estimated for each individual. These
results were compared with the true status and the coeffi-
cients from the model that best discriminated between
positive and negative biopsy were used to estimate the risk
score. Risk factors that were not statistically significant
predictors of positive repeat biopsy were also included
into the risk predictor model and to the risk score estima-
tion as this could increase predictive power. Although
DRE findings and previous HGPIN did not increase the
predictive power of the statistical model, they were
included in the risk score calculations as a consequence of
their assumed clinical importance.
Probability of positive repeat biopsy was estimated as the
expit (α + β1 x1 + β2 x2 ... βn xn ) of the model where, β rep-
resents the coefficient and x the variable used in the risk
score: age at biopsy, previous HGPIN, DRE findings, vol-
ume of the prostate, serum level of PSA and free-to-total
PSA, and PSA velocity. The risk score was calculated for
each subject with no missing data points in the selected
risk factors.
To assess performance of the risk score with respect to pre-
dicting positive repeat biopsy, receiver operating charac-
teristic (ROC) curves were plotted for the risk scores. The
area under the curve (AUC) and 95% confidence intervals
(CI) were then estimated. A larger area under the ROC
curve reflects better performance of a diagnostic test. Sen-
sitivity, specificity, and positive (PPV) and negative pre-
dictive values (NPV) and their 95% CI were calculated for
various cut-off points of the calculated risk score. The sen-
sitivity of the risk score is the proportion of men withPage 2 of 9
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score (percentage true positives). The specificity of the risk
score is the proportion of men without prostate cancer
who are correctly identified as such by the risk score (per-
centage true negatives). The positive predictive value of
the risk score is the proportion of men with a positive
result on the risk score who indeed have prostate cancer
identified on biopsy.
Analyses were performed using the statistics package Stata
9. (Stata Corp. Stata Statistical Software: release 9. 2005.
Texas: Stata Corporation)
Testing the risk score
The performance of the risk score in predicting prostate
cancer diagnosis on repeat biopsy was evaluated in an
independent sample of patients who had their repeat
prostate biopsy at Hospital (2) in the former West Anglia
Cancer Network.
The risk score for each subject was calculated. The scores
were tested for sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) in differ-
entiating men with and without prostate cancer diagnosis
on repeat biopsy.
Results
Developing the risk score -Hospital (1)
A total of 87 patients underwent repeat biopsy at Hospital
(1) during the study period, of whom 31% (27) had pros-
tate cancer diagnosis on repeat biopsy. Table 1 shows the
association between the outcome of prostate biopsy and
the study variables. Only velocity of PSA was statistically
significantly higher in men with positive repeat prostate
biopsy as compared to men with negative biopsy findings
Table 1: B Repeat prostate biopsy outcome and patient and prostate related factors, Hospital (1) sample
Variable Prostate cancer detected Prostate cancer not detected
No of patients Mean (SD) % No of patients Mean (SD) % P-value
N = 27 N = 59
Mean Age (years) 27 66.7 (7.8) 59 65.2 (7.5) 0.411
Prostate volume (ml) 22 51.1(27.3) 59 61.1 (24.5) 0.097
PSA (ng/ml) 27 12.4 (7.0) 59 11.7 (9.7) 0.735
Free-to-total PSA (%) 24 13.8 (7.4) 56 16.9 (8.4) 0.131
Velocity (ng/ml/year) 21 3.3 (3.2) 43 -0.8 (7.7) 0.023
DRE 0.443
1 (normal) 20 74.1 48 81.4
2 (abnormal) 7 25.9 11 18.6
Previous suspicious 0.867
Yes 2 7.4 5 8.5
No 25 92.6 54 91.5
Previous HGPIN 0.777
Yes 10 37.0 20 33.9
No 17 63.0 39 66.1
SD – standard deviation
P-value derived from logistic regression model
DRE 1 refers to a palpably normal gland, DRE 2 to a abnormal digital rectal examinationPage 3 of 9
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bles, velocity remained statistically significant predictor of
positive repeat biopsy (OR-trend = 1.34; 95%CI 1.03 –
1.74) (Table 2). Though the other variables were not sta-
tistically significant predictors individually, they were
included in the final logistic regression model as they
improved prediction.
A model that included the variables age, DRE findings,
previous HGPIN, volume of the prostate gland, serum lev-
els of PSA and free/total PSA, and PSA velocity had a prob-
ability of predicting prostate cancer of 51% compared to
24% in predicting absence of cancer on prostate repeat
biopsy.
The coefficients obtained from the logistic regression
model are shown in Table 2.
The performance of the risk score in differentiating
patients with positive and negative biopsy outcome is
shown in the receiver operating characteristic curve in Fig-
ure 1, with area under the curve (AUC) = 0.818 (95%CI
0.707 to 0.929).
The risk score cut off that maximised the sum of sensitivity
and specificity was derived from ROC analysis. This cut
point was 0.45, with sensitivity of 70% and specificity of
83%. A risk score > 0.45, would reduce 69% of the biop-
sies (43/62) while identifying 65% (13/20) of the cases.
Whereas a risk score > 0.2 would reduce 39% (24/62) of
the biopsies, while identifying 90% (18/20) of the
patients with prostate cancer and missing 10% (2/20) of
the patients with prostate cancer. Almost half of the
patients with a risk score > 0.2 are likely to have positive
prostate biopsy for prostate cancer (PPV = 47.4%; 95% CI
31.0% to 64.2%) (Table 3).
Validation of the risk score
Overall, during the study period, 23 patients had repeat
prostate biopsy in Hospital (2), of whom 7 patients
(30%) had prostate cancer diagnosis. The characteristics
of patients who had repeat biopsy in Hospital (2) are
given in Table 4.
The performance of the risk score in differentiating
patients with positive and negative biopsy outcome is
shown in the receiver operating characteristic curve in Fig-
ure 2, with AUC = 0.696 (95%CI 0.472 to 0.921). This
indicates that the risk model has performed well in an
independent sample. Using a cut point of 0.2 from the
model derived in Hospital (1), 100% (7/7) of patients
with positive repeat biopsy were correctly identified.
Discussion
Clinicians use various triggers for proceeding to repeat
prostate biopsies. Serum PSA, (which may be age-
adjusted), age, DRE findings, free-to-total PSA ratio, tran-
sition zone PSA density, standard PSA density, PSA veloc-
ity and the finding of HGPIN on initial biopsy have all
been used in this setting [1-5].
The predictive value of these individual factors is limited,
however, and this has led to attempts to refine the predic-
tion process and reduce the frequency of unnecessary
repeat biopsies. Artificial neural networks and nomo-
grams have been used to this end [11-14] but have not
gained wide acceptance in clinical practice.
The detection rate of cancer on second and further biop-
sies is thought to be lower than the initial procedure. Kat-
tan's group showed that the rate decreased from 19.5% in
the second biopsy to 13.5% after 5 or more biopsy ses-
sions [11]. This data and previous studies were, however,
based on initial sextant biopsies. In our study, the rate of
positive biopsies remained steady at 30%, and the distri-
bution of cancer grade did not change suggesting that
even in the era of extended core prostate biopsies initial
benign biopsies do not preclude a diagnosis of significant
cancer on subsequent investigation.
Identifying those men who require repeat biopsy whilst
avoiding unnecessary biopsies is not straightforward.
Djavan found that free-to-total PSA ratio and transition
zone PSA density were useful predictive factors with AUCs
of 74% and 69% [13]. Keetch et al have shown PSA den-
sity and PSA velocity to be better predictors [15] suggest-
ing that using more than one variable in determining
further biopsy is beneficial, but that the ideal combina-
tion is unknown.
Table 2: Adjusted β-coefficients and 95% confidence intervals for 
each risk factor, Hospital (1) sample
Variable Adjusted β-coefficient 95%CI
Age (yrs) 0.109 -0.004 0.221
DRE 0.093 -1.536 1.722
Previous HGPIN -0.120 -1.652 1.412
Volume (ml) -0.002 -0.030 0.026
PSA (ng/ml) -0.100 -0.212 0.012
Free-to-total (%) -0.119 -0.233 -0.005
Velocity (ng/ml/year) 0.293 0.029 0.557
constant -5.358 -12.389 1.672
* Adjusted for all the other variables in the modelPage 4 of 9
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that can predict the presence of cancer, and this model
was validated in a second repeat biopsy population with
an AUC of 71% [14].
Gallo [16] and Akhavan [17] have recently questioned the
predictive value of HGPIN in repeat biopsy, and our
model supports this view, as adding this variable to the
regression model did not increase the accuracy of predic-
tion. However, other authors have suggested that the find-
ing of multifocal HGPIN should be viewed with more
suspicion [18].
Kattan showed that incorporating multiple variables can
vastly improve on the predicted probability of having
prostate cancer [11]. We have adapted this approach to
the extended core repeat prostate biopsy population in a
UK setting, and improved the accuracy through adding
the additional variables of prostate volume and free-to-
total PSA ratio.
This nomogram (AUC 0.82, 95%CI 0.71 – 0.93) per-
formed favourably when compared with Kattan's which
had an AUC of 0.75. This may be a result of the incorpo-
ration of additional variables to the model. This predictive
tool is based on men who present either with symptoms,
or as a result of opportunistic screening. Whether this pre-
dictive tool is applicable to a setting where PSA testing for
screening purposes is more widely available needs to be
investigated. This model has been internally validated,
but re-validation on external populations should be the
next step.
The decision to repeat a prostate biopsy must be made
after informed discussion between clinician and patient,
following a multi-disciplinary team meeting case discus-
Receiver operating characteristic curve for the performance of risk score in identifying patients with prostate cancer diagnosis on rep at biopsy, Hospital (1) sampleFigure 1
Receiver operating characteristic curve for the performance of risk score in identifying patients with prostate 
cancer diagnosis on repeat biopsy, Hospital (1) sample.Page 5 of 9
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The probability of cancer on repeat biopsy generated by
this predictive tool reflects the probability that a man with
the same clinical parameters investigated in the same
manner as those included in this retrospective analysis
would have a positive repeat biopsy. This figure will be
interpreted by the patient according to his perception of
risk to inform his choice. A precise cut-off to trigger a
repeat biopsy is difficult to produce, and will vary accord-
ing to an individual patient's and urologist's perception of
risk, however, using a calculated risk score threshold for
re-biopsy of 0.45 (sensitivity 70%, specificity 83%) would
reduce the number of unnecessary biopsies in this study
(absolute reduction 69%) while identifying 65% of the
cancers. Alternatively a more conservative approach using
a risk-score threshold for biopsy of > 0.2 would reduce the
number of biopsies by 39% while identifying 90% of
patients with cancer. As such this study has policy impli-
cations. Implementing such a threshold risk score to trig-
ger repeat biopsy could reduce the number of repeat
biopsies in the UK by up to 4100 per year, equating to a
saving of €1.25 million, prevention of 40 life-threatening
hospital admissions for urinary sepsis, and 200 fewer uri-
nary tract infections.
Strengths of the study
The predictive tool was developed based on data from one
population sample and was tested in an independent
sample. Application of the risk scores to an independent
sample with good and comparable performance supports
the validity of the developed risk score model. A webtool
has been developed which is accessible, easy to use, and is
based on parameters readily available to the clinician dur-
ing an outpatient consultation. This facilitates discussion
Table 3: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and 95% confidence intervals (CI) at 
different risk score cut points, Hospital (1) sample
Risk score cut point Sensitivity Specificity PPV NPV
95% CI % 95% CI % 95% CI % 95% CI
> 0.1 90.0 68.3 98.8 38.1 23.6 54.4 40.9 26.3 56.8 88.9 65.3 98.6
> 0.2 90.0 68.3 98.8 52.4 36.4 68 47.4 31.0 64.2 91.7 73.0 99
> 0.3 75.0 50.9 91.3 71.4 55.4 84.3 55.6 35.3 74.5 85.7 69.7 95.2
> 0.4 70.0 45.7 88.1 83.3 68.6 93.0 66.7 43.0 85.4 85.4 70.8 94.4
> 0.45 65.0 40.8 84.6 85.7 71.5 94.6 68.4 43.4 87.4 83.7 69.3 93.2
> 0.5 55.0 31.5 76.9 88.1 74.4 96.0 68.8 41.3 89.0 80.4 66.1 90.6
> 0.6 35.0 15.4 59.2 95.2 83.8 99.4 77.8 40.0 97.2 75.5 61.7 86.2
> 0.7 10.0 1.2 31.7 97.6 87.4 99.9 66.7 9.4 99.2 69.5 56.1 80.8
> 0.8 0.0 0.0 16.8 97.6 87.4 99.9 0.0 0.0 97.5 67.2 54.0 78.7Page 6 of 9
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Table 4: The association between the outcome of prostate biopsy and patient and prostate related factors, Hospital (2) sample
Variable Prostate cancer detected Prostate cancer not detected
No of patients Mean (SD) % No of patients Mean (SD) % P-value
N = 7 N = 16
Age 7 66.6 (5.2) 16 62.8 (6.7) 0.202
Prostate volume 7 35.0 (15.3) 16 49.8 (9.3) 0.025
PSA 7 15.9 (17.7) 16 7.9 (3.0) 0.189
Free/total PSA (%) 7 50.1 (26.3) 15 25.3 (19.9) 0.039
Velocity 7 4.3 (7.8) 16 0.8 (1.9) 0.256
DRE 16 0.457
1 (normal) 7 100.0 15 93.7
2 (abnormal) 0 0.0 1 6.3
Previous suspicious 0.907
Yes 1 14.3 2 12.5
No 6 85.7 14 87.5
Previous HGPIN 0.095
Yes 0 0.0 5 31.2
No 7 100.0 11 68.8
SD – standard deviation
P-value derived from logistic regression model
BMC Urology 2009, 9:7 http://www.biomedcentral.com/1471-2490/9/7
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Receiver operating characteristic curve for the performance of risk score in identifying patients with prostate cancer diagnosis on rep at biopsy, Hospital (2) sampleFigure 2
Receiver operating characteristic curve for the performance of risk score in identifying patients with prostate 
cancer diagnosis on repeat biopsy, Hospital (2) sample.
Example screenshot of Webtool (available at http://www.ck-net.com/clients/camurology/)Figure 3
Example screenshot of Webtool (available at http://www.ck-net.com/clients/camurology/).
BMC Urology 2009, 9:7 http://www.biomedcentral.com/1471-2490/9/7of the risk estimates in real time with the patient and fur-
ther management planned in an informed fashion (Figure
3).
Limitations
The risk prediction model and the validation are based on
a small sample size. Nevertheless, the model had high pre-
dictive accuracy of 82% and has been validated on a small
external sample. This is a pilot model pending further
work on a larger sample size from different regions of the
UK. Repeat prostate biopsy is clearly not performed on all
patients and as such a true sensitivity and specificity for
the test are impossible to determine. Patients were filtered
through clinical judgement. However, as the data are
derived over a short period of time, then clinical decision
and investigation are likely to be comparable among the
patients undertaking repeat biopsy.
This tool is not designed to replace clinical judgement.
Once biopsy is considered, the tool will assist in informed
decision making.
Conclusion
We have developed a web-based predictive tool for a UK
population which is comparable to previous published
predictive nomograms to aid decision-making in men
with persistently abnormal PSA who are considering a
repeat prostate biopsy. Using such risk score prediction
model in clinical practice, could help in forming a strategy
for reducing the number of unnecessary repeat biopsies.
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